Objective: To determine the therapeutic effect of lisuride maleate on premenstrual mastalgia in premenopausal women.
Design: Double-blind randomized prospective study.
Setting: Department of obstetrics and gynecology at a university hospital.
Patient(s): Sixty women with premenstrual mastalgia were included in the study. Study and control groups consisted of 30 women each.
Intervention(s): Women enrolled in the study and control group were given one tablet daily (0.2 mg) of lisuride maleate or placebo orally for 2 months. Severity of mastalgia was evaluated using the visual analog scale.
Main Outcome Measure(s): Severity of mastalgia and side effects of the drug administered.
Result(s): Mastalgia subsided significantly in women receiving lisuride maleate compared with controls. There were no significant side effects from lisuride maleate. Prolactin levels decreased significantly in the group receiving lisuride, which correlated well with pain resolution.
Conclusion(s): Lisuride maleate may be useful for the symptomatic treatment of premenstrual mastalgia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0015-0282(01)01668-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A comparative study of effects of DOM and lisuride on neuronal activity in nucleus accumbens of freely moving rats.
Eur J Pharmacol
January 2025
State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Key Laboratory of Neuropsychopharmacology, Beijing Institute of Pharmacology and Toxicology, 27th Taiping Road, 100850, Beijing, China. Electronic address:
Article Synopsis
- DOM and lisuride are both chemical compounds that act as partial agonists on 5-HT receptors, with DOM being hallucinogenic and lisuride lacking these properties.
- A study using electrophysiological techniques on rats found that both drugs increased theta power and oscillation frequency but differed in their effects on medium spiny neurons and fast-spiking interneurons.
- These findings highlight similarities that may help explain their effects on behavior, while also pointing out critical differences in neuronal activity that could account for the distinct hallucinogenic effects of DOM compared to the non-hallucinogenic lisuride.
Neurochemical characterization of 5-HTR partial agonists with simultaneous PET-MRI.
J Cereb Blood Flow Metab
November 2024
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, USA.
Article Synopsis
- This study investigates the effects of different serotonin 2A receptor (5-HTR) agonists, such as psilocybin, lisuride, and 25CN-NBOH, to understand their potential in psychedelic drug applications.
- Using advanced imaging techniques like PET and phMRI on nonhuman primates, the researchers evaluated how these agonists affect brain blood flow and receptor occupancy.
- Findings suggest that mixed agonists like psilocybin and lisuride create complex blood volume responses while 25CN-NBOH leads to simpler responses, shedding light on how these drugs could be used to treat psychiatric disorders.
The distinct subjective effects that define psychedelics such as LSD, psilocybin or DOI as drug class are causally linked to activation of the serotonin 2A receptor (5-HT R). However, some aspects of 5-HT R pharmacology remain elusive, such as what molecular drivers differentiate psychedelic from non-psychedelic 5-HT R agonists. We developed an ex vivo platform to obtain snapshots of drug-mediated 5-HT R engagement of the canonical G pathway in native tissue.
View Article and Find Full Text PDFDemocracy: A Method to Capitalise on Prior Drug Discovery Efforts to Highlight Candidate Drugs for Repurposing.
Int J Mol Sci
May 2024
Bioinformatics Department, The Cyprus Institute of Neurology and Genetics, Nicosia 2370, Cyprus.
In the area of drug research, several computational drug repurposing studies have highlighted candidate repurposed drugs, as well as clinical trial studies that have tested/are testing drugs in different phases. To the best of our knowledge, the aggregation of the proposed lists of drugs by previous studies has not been extensively exploited towards generating a dynamic reference matrix with enhanced resolution. To fill this knowledge gap, we performed weight-modulated majority voting of the modes of action, initial indications and targeted pathways of the drugs in a well-known repository, namely the Drug Repurposing Hub.
View Article and Find Full Text PDFTesting of putative antiseizure medications in a preclinical Dravet syndrome zebrafish model.
Brain Commun
April 2024
Epilepsy Research Laboratory and Weill Institute for Neuroscience, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143, USA.
Dravet syndrome is a severe genetic epilepsy primarily caused by mutations in a voltage-activated sodium channel gene (). Patients face life-threatening seizures that are largely resistant to available anti-seizure medications. Preclinical Dravet syndrome animal models are a valuable tool to identify candidate anti-seizure medications for these patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!